Cargando…
Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results"
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891755/ https://www.ncbi.nlm.nih.gov/pubmed/33600462 http://dx.doi.org/10.1371/journal.pone.0245480 |
| _version_ | 1783652767443714048 |
|---|---|
| author | Mühlbacher, Axel C. Sadler, Andrew |
| author_facet | Mühlbacher, Axel C. Sadler, Andrew |
| author_sort | Mühlbacher, Axel C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7891755 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Public Library of Science |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78917552021-03-01 Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results" Mühlbacher, Axel C. Sadler, Andrew PLoS One Formal Comment Public Library of Science 2021-02-18 /pmc/articles/PMC7891755/ /pubmed/33600462 http://dx.doi.org/10.1371/journal.pone.0245480 Text en © 2021 Mühlbacher, Sadler http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| spellingShingle | Formal Comment Mühlbacher, Axel C. Sadler, Andrew Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results" |
| title | Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results" |
| title_full | Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results" |
| title_fullStr | Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results" |
| title_full_unstemmed | Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results" |
| title_short | Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results" |
| title_sort | comment on the paper "cost-effectiveness of sofosbuvir in hepatitis c genotype 1 infection in germany: a reanalysis of published results" |
| topic | Formal Comment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891755/ https://www.ncbi.nlm.nih.gov/pubmed/33600462 http://dx.doi.org/10.1371/journal.pone.0245480 |
| work_keys_str_mv | AT muhlbacheraxelc commentonthepapercosteffectivenessofsofosbuvirinhepatitiscgenotype1infectioningermanyareanalysisofpublishedresults AT sadlerandrew commentonthepapercosteffectivenessofsofosbuvirinhepatitiscgenotype1infectioningermanyareanalysisofpublishedresults |